Dusetzina SB, Huskamp HA, Jazowski SA, et al. - In this observational study of administrative claims from 2008-2017 of people initiating tyrosine kinase inhibitors (TKI) for chronic myeloid leukemia (CML) or immunomodulatory drugs for multiple myeloma, experts assessed the relationship between oral oncology parity law adoption and anti-cancer medication use for people with CML or multiple myeloma. Amongst individuals initiating TKIs (N = 2,082) or immunomodulatory drugs (N = 3,326), no statistically important variations in adherence or discontinuation related to parity were seen, however, it gave reduced patient out-of-pocket payments for some people.